Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
2(15%)
Results Posted
40%(4 trials)

Phase Distribution

Ph phase_1
10
77%
Ph phase_2
1
8%
Ph phase_3
2
15%

Phase Distribution

10

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
10(76.9%)
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
2(15.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(10)

Detailed Status

Completed10
Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 110 (76.9%)
Phase 21 (7.7%)
Phase 32 (15.4%)

Trials by Status

completed1077%
not_yet_recruiting18%
recruiting215%

Recent Activity

2 active trials
Showing 5 of 13
recruitingphase_3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

NCT07071623
completedphase_1

A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)

NCT06580587
not_yet_recruitingphase_1

A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)

NCT07528508
recruitingphase_3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

NCT07044297
completedphase_1

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

NCT07025551
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07071623Phase 3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Recruiting
NCT06580587Phase 1

A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)

Completed
NCT07528508Phase 1

A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)

Not Yet Recruiting
NCT07044297Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Recruiting
NCT07025551Phase 1

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

Completed
NCT06295796Phase 1

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

Completed
NCT07063238Phase 1

A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)

Completed
NCT06045507Phase 2

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

Completed
NCT06893081Phase 1

A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

Completed
NCT06816043Phase 1

A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

Completed
NCT05494736Phase 1

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Completed
NCT06783192Phase 1

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

Completed
NCT03615183Phase 1

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13